PHP78 System-Wide Impact of Payment Schemes for Integrated Care of Chronic Diseases in Europe: Evidence from an Empirical Analysis

Abstract

health care use resulting from ADRs and STEs. The prevalence-based cost-of-illness analysis included direct costs for drugs, from the Swedish Prescribed Drug Register, and health care use, based on national statistics, during a 30 day study-period. RESULTS: Of the 7099 respondents, 1,377 reported at least one ADE and 943 reported an ADR or STE. During the study-period, respondents with/without self-reported ADEs respectively reported 124/164 general practitioner visits, 182/310 nurse visits, 191/310 specialist physician or emergency department visits, 39/48 home-health care visits, 159/283 other somatic visits, 4/4 psychiatrist visits, 120/72 other psychiatric visits, 20/17 hospitalizations, 267/228 health care contacts by phone or mail, and the use of 3,908/8,663 prescription medicines. The average direct cost per respondent was higher among respondents reporting ADEs compared to those not reporting an ADE (mean Ϯ SD): EUR 202.0 Ϯ 901.2 vs. EUR 61.2 Ϯ 356.9 (pϽ0.001). The average direct costs of respondents reporting at least one ADR or STE were EUR 239.6 Ϯ 950.7, and costs resulting from ADRs or STEs were EUR 16.8 Ϯ 150.5 and EUR 33.4 Ϯ 266.9, respectively. CONCLUSIONS: According to our results, the resource use and costs associated with ADEs are extensive, and occurs both in hospitals and primary care. There is a need to further examine the relationships between self-reported ADEs and the high overall COI, and study the indirect costs of self-reported ADEs.